Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyEmblemHealth fecal incontinence Coverage Update | …
    Ask Trek AI about this page
    CurrentEmblemHealthPolicy MG.MM.ME.63bC5

    Fecal Incontinence Treatment

    Customize your policy alerts

    Sign up for EmblemHealth Policy MG.MM.ME.63bC5 alerts

    Get alerted when Policy MG.MM.ME.63bC5 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This clinical guideline defines when treatments and procedures for severe fecal incontinence are considered medically necessary or not for EmblemHealth members and describes required documentation for medical review.

    Policy Summary
    PayerEmblemHealth
    PolicyFecal Incontinence Treatment
    Policy CodePolicy MG.MM.ME.63bC5
    Change TypeAdded investigational autologous muscle cell therapy (1001T)
    Effective DateJun 12, 2026
    Last ReviewJun 12, 2026
    Next Review DateJun 12, 2026
    Key ActionSubmit prior authorization with clinical evidence showing the member meets medical necessity criteria before approval of neuromodulation or implant procedures.
    SourceLink
    POLICY UPDATE CHANGES

    Autologous muscle cell therapy (injection of muscle progenitor cells into the external anal sphincter) is listed as investigational / not considered medically necessary, effective 1/1/2026 (code 1001T).

    11procedures/interventions listed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥50%
    trial improvement threshold
    ≥18minimum age (Acticon)
    0963T,1001Texample novel codes

    Coverage Criteria for Fecal Incontinence Treatments

    Medically necessary treatments for severe fecal incontinence

    Covered when ANY of the following are met and conservative interventions have failed:

    1: Anal sphincter repair
    2: Colostomy - member has failed/is not a candidate for medical interventions or surgical sphincter repair (e.g., post-anal repair, sphincteroplasty or total pelvic floor repair, biofeedback pelvic training). Check member benefits for colostomy coverage.
    3: Acticon™ Neosphincter artificial bowel sphincter for members ≥ 18 years of age who have failed or are not candidates for medical interventions or surgical sphincter repair (e.g., post-anal repair, sphincteroplasty, or total pelvic floor repair).Member ≥ 18 years

    Contraindications such as irreversibly obstructed proximal bowel or poor surgical/anesthesia candidacy preclude use (see Limitations/Exclusions).

    4: Sacral nerve stimulation (sacral neuromodulation) for chronic fecal incontinence when member has had an inadequate response to conservative treatments and has a weak but structurally intact anal sphincter.≥ 50% improvement on a 2–3 week temporary percutaneous peripheral nerve electrode trial required prior to permanent implant

    A 2–3-week temporary percutaneous trial must be completed; permanent implantation (e.g., InterStim®) is considered medically necessary only if trial shows ≥50% improvement in incontinence symptoms.

    The Acticon Neosphincter artificial bowel sphincter is not considered medically necessary when the specific coverage criteria are not met or when use is contraindicated. Examples of contraindications include incontinence complicated by an irreversibly obstructed proximal segment of bowel or when the member is a poor candidate for surgery or anesthesia. Approval requires documentation that all required clinical and eligibility criteria have been satisfied prior to coverage.

    The following interventions are not considered medically necessary due to insufficient evidence of therapeutic value: radiofrequency energy delivery (e.g., Secca Therapy), perianal electrical stimulation, injectable bulking agents (e.g., Solesta®; CPT 0963T), vaginal bowel control systems (e.g., eclipse system™ — note: covered for Medicare members only), injection of autologous myoblast cells, injection of mesenchymal stem cells, topical estrogen, tibial nerve stimulation, pudendal nerve terminal motor latency testing, and the Interna® Dermal Regeneration FENIX™ Continence Restoration System.

    Specific interventions listed in the Limitations and Exclusions section are deemed not medically necessary because there is insufficient evidence demonstrating therapeutic benefit; this includes injectable bulking agents (e.g., Solesta®), tibial nerve stimulation, Secca Therapy, autologous/cell-based injections, and other listed devices and biologic therapies (including autologous muscle cell therapy, CPT 1001T, effective 1/1/2026).

    Procedure, Supply, and Diagnosis Codes

    Procedure and supply codes (implantation, programming, devices)CPT/HCPCS
    64561Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed.
    64581Incision for implantation of neurostimulator electrodes; sacral nerve (transforaminal placement).
    64590Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling.
    95972Electronic analysis of implanted neurostimulator pulse generator system; complex spinal cord, or peripheral neurostimulator pulse generator/transmitter, with programming.
    L8680Implantable neurostimulator electrode, each.
    L8681Patient programmer (external) for use with implantable programmable implantable neurostimulator pulse generator.
    L8682Implantable neurostimulator radiofrequency receiver.
    Device supply codesHCPCS
    L8683Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver.
    L8684Radiofrequency transmitter (external) for use with implantable sacral root neurostimulator receiver for bowel and bladder management, replacement.
    L8685Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
    L8686Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension.
    L8687Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
    L8688Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension.
    L8689External recharging system for battery (internal) for use with implantable neurostimulator.
    L8695External recharging system for battery (external) for use with implantable neurostimulator.
    ICD-10 diagnoses (examples listed)ICD-10
    A04.71Enterocolitis due to Clostridium difficile, recurrent.
    A04.72Enterocolitis due to Clostridium difficile, not specified as recurrent.
    inv-09: Percutaneous sacral nerve stimulation trial success threshold
    Trial duration2–3 week temporary percutaneous peripheral nerve electrode trial
    Success threshold≥ 50% improvement in incontinence symptoms compared with baseline
    Required before permanent implantTemporary percutaneous trial must be completed prior to consideration of permanent implantable pulse generator (e.g., InterStim®)
    inv-10: Age threshold for Acticon Neosphincter
    Minimum ageMember is ≥ 18 years of age
    Device

    Provider Requirements and Prior Authorization

    Prior Authorization

    Prior authorization required for neuromodulation and implants

    Prior authorization review is required before approval of procedures such as sacral neuromodulation and implantation of neurostimulator devices; submit the requested authorization for review along with clinical evidence that the member meets medical necessity criteria.

    • Applicable CPT/HCPCS codes include: 64561, 64581, 64590, 95972 and HCPCS L8680–L8695 (see coding section).
    Step Therapy

    Document failed conservative care and complete staged neuromodulation trial

    Conservative interventions (dietary management, pharmacotherapy, pelvic floor strengthening) must have failed before considering advanced treatments; for sacral neuromodulation, a 2–3 week percutaneous temporary electrode trial demonstrating ≥50% improvement is required prior to permanent implantation.

    • Conservative care examples: dietary management, pharmacotherapy, strengthening exercises.
    • Temporary percutaneous peripheral nerve electrode trial duration: 2–3 weeks; success threshold: ≥50% improvement in incontinence symptoms.

    Background and Clinical Context

    Anal incontinence is defined as the involuntary loss of solid or liquid feces or flatus. Severe fecal incontinence refers to involuntary loss of solid or liquid feces or flatus occurring on a weekly or more frequent basis. Initial management typically comprises conservative medical interventions such as dietary management, pharmacotherapy, and pelvic floor strengthening exercises; advanced surgical or device-based treatments are considered when conservative measures fail.

    Definitions

    inv-16: Anal incontinence
    DefinitionInvoluntary loss of solid or liquid feces or flatus
    Clinical relevanceUsed as the baseline definition for identifying fecal incontinence severity and treatment candidacy
    SourceEmblemHealth definitions table
    inv-17: Severe fecal incontinence
    DefinitionInvoluntary loss of solid or liquid feces or flatus on a weekly, or more, frequent basis
    Severity implicationDenotes 'severe' fecal incontinence for purposes of determining eligibility for advanced therapies
    Use in criteria

    Revision History and Policy Changes

    2025-12-08policy_revision

    Added autologous muscle cell therapy as investigational (autologous muscle cell therapy; CPT 1001T).

    2025-06-13policy_revision

    Transferred policy content to individual company branded template.

    2022-05-13policy_adoption

    EmblemHealth ConnectiCare adopted the clinical criteria of parent corporation EmblemHealth.

    Policy Summary
    PayerEmblemHealth
    PolicyFecal Incontinence Treatment
    Policy CodePolicy MG.MM.ME.63bC5
    Change TypeAdded investigational autologous muscle cell therapy (1001T)
    Effective DateJun 12, 2026
    Last ReviewJun 12, 2026
    Next Review DateJun 12, 2026
    Key ActionSubmit prior authorization with clinical evidence showing the member meets medical necessity criteria before approval of neuromodulation or implant procedures.
    SourceLink
    On This Page
    Coverage Criteria for Fecal Incontinence TreatmentsProcedure, Supply, and Diagnosis CodesProvider Requirements and Prior AuthorizationBackground and Clinical ContextDefinitionsRevision History and Policy Changes
    Acticon™ Neosphincter artificial bowel sphincter
    ContextUsed when member has failed or is not a candidate for medical interventions or surgical sphincter repair
    Documentation Required

    Submit required clinical evidence with authorization request

    The treating physician or primary care provider must submit clinical evidence that the member meets the guideline criteria for the requested treatment or surgical procedure to allow EmblemHealth to properly review the request.

    • Include documentation of prior conservative treatments attempted and their outcomes, physical exam findings (e.g., weak but structurally intact sphincter when applicable), and results of any temporary neuromodulation trial.
    • For Acticon Neosphincter requests, document member age (≥18 years) and contraindications assessment.
    Denial Risk

    Documentation omission may cause denial

    Failure to submit the required clinical evidence and documentation will prevent proper preauthorization or post-payment review and may lead to denial of the request.

    • Missing documentation of failed conservative care, temporary trial results (for neuromodulation), or physician verification of guideline criteria increases risk of denial.
    Applied as the clinical threshold for considering procedures listed as medically necessary after failed conservative care
    inv-18: Conservative medical interventions
    ExamplesDietary management, pharmacotherapy, strengthening (pelvic floor) exercises
    RoleRequired to have failed before advanced treatments (e.g., sacral nerve stimulation, Acticon Neosphincter) are considered
    DocumentationClinical evidence of failed conservative interventions must be submitted for prior authorization review
    2017-07-14policy_revision

    Added Interna® Dermal Regeneration FENIX™ Continence Restoration System as investigational.